Edition:
India

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

7.70USD
2:29am IST
Change (% chg)

$0.19 (+2.53%)
Prev Close
$7.51
Open
$7.57
Day's High
$7.86
Day's Low
$7.44
Volume
76,358
Avg. Vol
60,508
52-wk High
$27.77
52-wk Low
$7.20

Summary

Name Age Since Current Position

Douglas Treco

President, Chief Executive Officer, Co-Founder, Director

Jeffrey Johnston

Senior Vice President, Chief Medical Officer

Alonso Ricardo

Senior Vice President of Research & Development

Kerry Black

Executive Director, Operations

Edward Mathers

57 Board Member

Biographies

Name Description

Douglas Treco

Mr. Douglas (Doug) A. Treco, Ph.D. is the Co-Founder, President and Chief Executive Officer, Member of the Board of Directors of Ra Pharmaceuticals Inc. Doug has been the CEO of Ra Pharma™ since its inception and serves on the Company’s Board of Directors. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT, acquired in 2005 by Shire plc),a multi-platform biopharmaceutical company developing protein and gene therapy products. In his position as Senior Vice President of Research and Development, Doug established and directed TKT’s gene activation and protein production efforts, which led to the approval of the biopharmaceutical products Dynepo™, Replagal®, Elaprase®, and Vpriv™. Previously, he was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School. He has authored numerous peer-reviewed publications and holds over 35 U.S. and European patents in the areas of protein production, gene mapping, and gene therapy. Doug is also an Entrepreneur-in-Residence with Morgenthaler Ventures. Doug received his PhD in biochemistry and molecular biology from SUNY at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.

Jeffrey Johnston

Mr. Jeffrey M Johnston, MD, FACP, is the Senior Vice President and Chief Medical Officer of the Company. Jeff joined Ra in the beginning of 2016 and brings over 27 years of experience as a leader of new drug development in the pharmaceutical and biotechnology industry. He was previously Chief Medical Officer and Senior Principal Clinical Scientist at Ironwood Pharmaceuticals from 2005 until 2016, where he built a strong and fully integrated clinical development function and successfully led the clinical development of linaclotide from Phase 1 through NDA approval and launch. Dr. Johnston was also a member of the company’s joint development committees with its international partners, leading clinical development in Europe and Asia. Prior to Ironwood, Dr. Johnston served as Vice President and Chief Development Officer at Critical Therapeutics in Lexington, MA and was previously Vice President of Clinical Research at Triangle Pharmaceuticals in Durham, NC Prior to that he held roles of increasing responsibility in clinical development at Burroughs Wellcome/GlaxoWellcome/GlaxoSmithKline in Research Triangle Park, NC. Jeff graduated summa cum laude from Davidson College in North Carolina and received his MD degree at Duke University.

Alonso Ricardo

Mr. Alonso Ricardo, PhD is the Senior Vice President of Research & Development of the Company. Alonso Ricardo joined Ra in 2010 and has held a variety of roles with increasing responsibility. Alonso received a PhD in Chemistry from the University of Florida working under the supervision of Professor Steven A. Benner. Following graduation, he joined the faculty of the Universidad de los Andes in Bogota, Colombia where he performed research in peptide macrocyclization and Bioorganic Chemistry. In 2006 he became an HHMI Research Associate with Professor Jack W. Szostak, working in Synthetic Biology at Harvard University and the Massachusetts General Hospital.

Kerry Black

Ms. Kerry Black is the Executive Director, Operations of Ra Pharmaceuticals Inc. Kerry Black, MS, MBA, Executive Director, Operations Kerry joined Ra Pharma™ in March of 2010 as the Senior Director of Operations. She has over 20 years experience in the biotechnology industry working both as a Research Scientist and Operations Director. She has spent the last 16 years specializing in early stage companies, building business and operational infrastructure, including as an early employee at Critical Therapeutics, TetraPhase Pharmaceuticals and SetPoint Medical Corporation. Kerry received dual Bachelor of Science Degrees in molecular and cellular biology and biochemistry from the University of Maine. She received a Master of Chemistry Degree from the University of Massachusetts at Lowell and an MBA from the F.W. Olin School of Management at Babson College.

Edward Mathers

Mr. Edward Mathers is a Director of Ra Pharmaceuticals, Inc. Ed Mathers joined NEA as a Partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments. He is a director of Liquidia Technologies, Ra Pharmaceuticals, Rhythm Pharmaceuticals, Envisia Therapeutics, Synlogic, Mirna Therapeutics, Lumos Pharma and Ziarco. He is also a member of NC State’s College of Sciences Foundation board. Previously he was a board member of Lumena (sold to Shire), Plexxikon (sold to Daiichi Sankyo), Intarcia, Satori Pharmaceuticals, Southeast Bio, MedImmune, LLC, and the Biotechnology Industry Organization (BIO). Prior to joining NEA, Ed most recently served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. In this role, he was a member of the leadership team that executed the sale of the company to AstraZeneca for $15.6 billion in 2007. While at MedImmune, Ed was responsible for the company’s corporate and business development activities and led the company’s venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune in 2002, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Ed spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held sales and marketing positions of increasing responsibility. He earned his bachelor's degree in chemistry from North Carolina State University.

Basic Compensation

Options Compensation